atorvastatin for reduction of myocardial damage during angioplasty l.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Atorvastatin for Reduction of Myocardial Damage During Angioplasty PowerPoint Presentation
Download Presentation
Atorvastatin for Reduction of Myocardial Damage During Angioplasty

Loading in 2 Seconds...

play fullscreen
1 / 5

Atorvastatin for Reduction of Myocardial Damage During Angioplasty - PowerPoint PPT Presentation


  • 131 Views
  • Uploaded on

ARMYDA Trial. Atorvastatin for Reduction of Myocardial Damage During Angioplasty. Pasceri V, et al Circulation 2004;110:674-8. ARMYDA Trial. 153 patients scheduled for elective PCI irrespective of baseline lipid levels Randomized, double-blind. Atorvastatin 40 mg/d n=76. Placebo n=77.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Atorvastatin for Reduction of Myocardial Damage During Angioplasty' - arleen


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
atorvastatin for reduction of myocardial damage during angioplasty

ARMYDA Trial

Atorvastatin for Reduction of Myocardial Damage During Angioplasty

Pasceri V, et al

Circulation 2004;110:674-8

armyda trial
ARMYDA Trial

153 patients scheduled for elective PCI irrespective of baseline lipid levels

Randomized, double-blind

  • Atorvastatin
  • 40 mg/d
  • n=76
  • Placebo
  • n=77

Treatment for 7 days

  • Primary Endpoint:
    • Occurrence of MI, defined as a post-procedural increase of CK-MB >2 times above ULN

Circulation 2004;110:674-8

armyda trial3
ARMYDA Trial

Post-procedure MI

(>2x ULN)

p = 0.025

  • Primary endpoint of post-procedure MI (CKMB>2x ULN) ↓ in atorvastatin group vs placebo (Figure)
  • Presence of markers >1x ULN also ↓ in atorvastatin arm: CKMB 12% vs 35%, p=0.001; troponin I 20% vs 48% p=0.0004; myoglobin 22% vs 51%, p=0.0005

Circulation 2004;110:674-8

armyda trial4
ARMYDA Trial

Peak CK-MB

p = 0.007

Peak Troponin I

p = 0.0008

ng/mL

ng/mL

Circulation 2004;110:674-8

armyda trial5
ARMYDA Trial
  • Among patients undergoing elective PCI irrespective of baseline lipid levels, pre-treatment with atorvastatin was associated with a reduction in markers of myocardial injury post-procedure
  • LIPS trial showed reduction in long-term cardiac events associated with statin use in patients undergoing PCI; however, statin therapy was initiated post-procedure and effect on early myocardial injury was not evaluated
  • Mechanism of action for reduction of myocardial injury unclear but may be related to anti-inflammatory effect of statins
  • Further evaluation warranted